MTOR and renal cell carcinoma: Considering combinational therapy, vorinostat, (a hydroxamic acid class HDAC inhibitor) synergized with the anticancer activity of temsirolimus (inhibitor of mTOR pathway), both in a panel of RCC cell lines in vitro and in two xenograft models in vivo [251].